Written by MarketBeatUpdated August 17, 2025 ShareLink copied to clipboard. Key Points Theravance Biopharma's stock reached a new 52-week high of $11.89 following a strong earnings report that showed an EPS of $1.08, significantly beating analysts' expectations of -$0.12. Analysts have mixed views on the stock, with Jones Trading upgrading it to a "strong-buy" with a price target of $24.00, while Wall Street Zen downgraded it from "buy" to "hold." Insider activity revealed that SVP Rhonda Farnum sold 24,000 shares for a total of $264,000, indicating a 6.65% decrease in her ownership, amidst broader insider sales totaling 44,000 shares over the past 90 days. Want stock alerts on Theravance Biopharma? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts. Like this article? Share it with a colleague. Link copied to clipboard. Featured Articles and Offers3 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Out of 18,347 Cryptocurrencies... This is the ONLY OneFrom Crypto 101 Media (Ad)IBM: The Last Time This Happened, the Stock Rallied 35%By Sam Quirke | August 12, 2025Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAEBy Jeffrey Neal Johnson | August 13, 2025IPO Market Stays Hot With These 2 Debuting StocksBy Dan Schmidt | August 11, 2025Altucher: $900 to $108,000? Trump’s “Great Gain” Is HereFrom Paradigm Press (Ad)Alibaba Group (BABA) to Release Quarterly Earnings on ThursdayBy MarketBeat | August 17, 2025Data Centers Create a Bull Case for These Nuclear 3 StocksBy Gabriel Osorio-Mazilli | August 14, 2025 Recent Videos Stock ListsAll Stock Lists5G Biotech Blue Chip FAANG Gold Large Cap Marijuana Micro Cap Oil REITs Russell 2000 Small Cap Warren Buffett Investing ToolsCalendars and ToolsAnalyst RatingsCryptocurrency ScreenerCongressional TradingDividend IncreasesDividend CalculatorDividend CalendarEarnings AnnouncementsInsider TradesOptions Profit CalculatorPenny StocksPortfolio MonitoringShort InterestStock ComparisonsStock Market HolidaysStock Screener Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Written by MarketBeatUpdated August 17, 2025 ShareLink copied to clipboard. Key Points Theravance Biopharma's stock reached a new 52-week high of $11.89 following a strong earnings report that showed an EPS of $1.08, significantly beating analysts' expectations of -$0.12. Analysts have mixed views on the stock, with Jones Trading upgrading it to a "strong-buy" with a price target of $24.00, while Wall Street Zen downgraded it from "buy" to "hold." Insider activity revealed that SVP Rhonda Farnum sold 24,000 shares for a total of $264,000, indicating a 6.65% decrease in her ownership, amidst broader insider sales totaling 44,000 shares over the past 90 days. Want stock alerts on Theravance Biopharma? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts. Like this article? Share it with a colleague. Link copied to clipboard.
MarketBeat All Access